Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

Phase II clinical study results have revealed excellent safety and tolerability.
a representation of the human liver
Wider scope across a broad range of diseases

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

The company’s shares were last trading circa 54% higher intra-day, at $0.44.

A total of 133 non-alcoholic steatohepatitis (NASH) patients were enrolled into Immuron’s phase II NASH clinical study and were treated with either IMM-124E or placebo for 6 months.

Results demonstrate a statistically significant reduction of serum LPS levels

64.29% of patients treated with IMM-124E demonstrated a 15% or greater decrease in serum LPS levels compared with only 34.48% of patients showing a decrease for the placebo group, reaching statistical significance.

Importantly, no safety concerns or serious adverse events were associated with the study drug.

The 600mg and 1200mg doses were well tolerated and support the use of even higher doses and extended treatment periods in future clinical trials.

Wider scope across a broad range of diseases

Immuron’s study results offer evidence of a therapeutic mechanism of action and a clear direction for further NASH studies.

The growing literature implicating LPS in many diseases offers the potential for a much wider scope for LPS antagonism as a treatment modality.

With IMM-124E being the world’s first-in class oral LPS antagonist, the company has substantial opportunities across a broad range of diseases.

READ: Immuron achieves strong sales growth for travellers’ diarrhoea product

The company’s flag-ship product Travelan® achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017
Newswire
May 27 2016

Related Articles

test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use